OPRD1 encodes the delta-opioid receptor, a G-protein coupled receptor that binds endogenous enkephalins and other opioids 1. Ligand binding triggers conformational changes activating G-protein signaling, inhibiting adenylate cyclase activity and modulating neurotransmitter release through altered calcium and potassium currents [UniProt]. The receptor regulates pain perception and opiate-mediated analgesia, while also contributing to analgesic tolerance development [UniProt]. OPRD1 contains over 2,000 genetic variants with diverse functional consequences 1. The variants rs1042114 and rs569356 have characterized functions: rs1042114 disrupts receptor maturation and has been linked to Alzheimer's disease through reduced beta-amyloid production 1, while rs569356 affects OPRD1 expression and shows association with anorexia 1. Intronic variants (rs2236861, rs2236857, rs3766951) demonstrate reproducible associations with opioid addiction across populations 1. OPRD1 rs2234918 increases heroin dependence vulnerability 1.42-fold 2, while rs4654327 acts as both a methylation and expression quantitative trait locus associated with opioid use disorder 3. These addiction-linked variants function as cis-eQTLs for upstream PHACTR4, affecting cytoskeletal dynamics and synaptic plasticity 4. In males, OPRD1 polymorphisms influence morphine analgesia variability 5. Notably, OPRD1 expression is downregulated in psychopathy-associated neurons 6, suggesting broader neuropsychiatric relevance beyond pain and addiction.